A Phase 1 Study of Fosbretabulin in Combination With Everolimus in Neuroendocrine Tumors (Grades 1-3) That Have Progressed After at Least One Prior Regimen for Metastatic Disease

This is a single center, open label, phase I study involving grade I-III gastroenteropancreatic neuroendocrine tumors, consisting of a dose escalation Part A followed by an expansion cohort Part B. On Part A Patients will be treated with daily oral everolimus. Fosbretabulin will be administered IV either q3 weekly or q weekly based on PO CRM cohort. Part B: Once the investigators have established an MTD in Part A, the investigators will be treating 15 more patients at that dose combination. The primary and secondary objectives of the expansion cohort will be similar to Part A of the study, i.e., to establish a safety profile of the experimental drug combination and to collect and assess efficacy data. Patients will be treated with concurrent everolimus and fosbretabulin for 12 weeks.

开始日期2017-03-06

申办/合作机构

University of Kentucky

NCT01701349 / Withdrawn临床3期

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Fosbretabulin Tromethamine (CA4P) in Combination With Paclitaxel and Carboplatin in Anaplastic Thyroid Carcinoma (FACT2)

This is a multicenter, double-blind, placebo-controlled, randomized study of fosbretabulin given with chemotherapy (paclitaxel and carboplatin) compared to placebo given with chemotherapy (paclitaxel and carboplatin) in subjects with anaplastic thyroid cancer (ATC). The primary objective of the study is to determine overall survival. A maximum of 300 subjects will be recruited from approximately 75 multinational sites of which approximately 35 will be located in the United States.

开始日期2015-03-01

申办/合作机构

Oncotelic Therapeutics, Inc.

NCT02279602 / Completed临床2期

Rollover for Study OX4218s, A P2 Study to Investigate Safety and Activity of Fosbretabulin Tromethamine in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET With Elevated Biomarkers

Subjects achieving a clinical response in study OX4218s with a biomarker reduction or symptom response are eligible to enroll in this rollover study to continue once every three weeks fosbretabulin infusions for up to one year.

开始日期2014-12-01

申办/合作机构

Oncotelic Therapeutics, Inc.

100 项与康普瑞丁磷酸二钠相关的临床结果

登录后查看更多信息

100 项与康普瑞丁磷酸二钠相关的转化医学

登录后查看更多信息

100 项与康普瑞丁磷酸二钠相关的专利（医药）

登录后查看更多信息

765

项与康普瑞丁磷酸二钠相关的文献（医药）

2024-08-07·ACS Applied Materials & Interfaces

Peptide-IR820 Conjugate: A Promising Strategy for Efficient Vascular Disruption and Hypoxia Induction in Melanoma

Article

作者: Jiang, Mengmeng ; Zheng, Zhen ; Li, Gongyu ; Zhang, Hongxia ; Xing, Weiyu ; Zhao, Rui

Photothermal therapy (PTT) has emerged as a noninvasive and precise cancer treatment modality known for its high selectivity and lack of drug resistance. However, the clinical translation of many PTT agents is hindered by the limited biodegradability of inorganic nanoparticles and the instability of organic dyes. In this study, a peptide conjugate, IR820-Cys-Trp-Glu-Trp-Thr-Trp-Tyr (IR820-C), was designed to self-assemble into nanoparticles for both potent PTT and vascular disruption in melanoma treatment. When co-assembled with the poorly soluble vascular disrupting agent (VDA) combretastatin A4 (CA4), the resulting nanoparticles (IR820-C@CA4 NPs) accumulate efficiently in tumors, activate systemic antitumor immune responses, and effectively ablate melanoma with a single treatment and near-infrared irradiation, as confirmed by our in vivo experiments. Furthermore, by exploiting the resulting tumor hypoxia, we subsequently administered the hypoxia-activated prodrug tirapazamine (TPZ) to capitalize on the created microenvironment, thereby boosting therapeutic efficacy and antimetastatic potential. This study showcases the potential of short-peptide-based nanocarriers for the design and development of stable and efficient photothermal platforms. The multifaceted therapeutic strategy, which merges photothermal ablation with vascular disruption and hypoxia-activated chemotherapy, holds great promise for advancing the efficacy and scope of cancer treatment modalities.

2024-06-01·INVESTIGATIONAL NEW DRUGS

In vitro results with minimal blood toxicity of a combretastatin A4 analogue

Article

作者: Barreiro, Eliezer J ; Schumacher, Maria Lúcia ; Britos, Tatiane Nassar ; Lima, Lídia Moreira ; Petri, Giuliana ; da Costa Aguiar Alves Reis, Beatriz ; Haddad, Paula Silvia ; Ferreira, Fabio Furlan ; Mansano, Jaqueline Vital ; Chagas, Camila ; Fonseca, Fernando Luiz Affonso ; Pereira, Edimar Cristiano ; da Silva, Emerson Barbosa

Cancer is a disease caused by uncontrolled cell growth that is responsible for several deaths worldwide. Breast cancer is the most common type of cancer among women and is the leading cause of death. Chemotherapy is the most commonly used treatment for cancer; however, it often causes various side effects in patients. In this study, we evaluate the antineoplastic activity of a parent compound based on a combretastatin A4 analogue. We test the compound at 0.01 mg mL^- 1, 0.1 mg mL^- 1, 1.0 mg mL^- 1, 10.0 mg mL^- 1, 100.0 mg mL^- 1, and 1,000.0 mg mL^- 1. To assess molecular antineoplastic activity, we conduct in vitro tests to determine the viability of Ehrlich cells and the blood mononuclear fraction. We also analyze the cytotoxic behavior of the compound in the blood and blood smear. The results show that the molecule has a promising antineoplastic effect and crucial anticarcinogenic action. The toxicity of blood cells does not show statistically significant changes.

2024-06-01·Advanced materials (Deerfield Beach, Fla.)

Tumor Microenvironment Remodeling‐Mediated Sequential Drug Delivery Potentiates Treatment Efficacy

Article

作者: Kong, Chaoying ; Shen, Na ; Chen, Xuesi ; Liu, Fuyao ; Gu, Zhen ; Lv, Jianlin ; Liu, Ya ; Li, Yanran ; Wang, Jinqiang ; Tang, Zhaohui ; Xu, Yajun

Abstract:

Toll‐like receptor 7/8 agonists, such as imidazoquinolines (IMDQs), are promising for the de novo priming of antitumor immunity. However, their systemic administration is severely limited due to the off‐target toxicity. Here, this work describes a sequential drug delivery strategy. The formulation is composed of two sequential modules: a tumor microenvironment remodeling nanocarrier (poly(l‐glutamic acid)‐graft‐methoxy poly(ethylene glycol)/combretastatin A4, termed CA4‐NPs) and an immunotherapy nanocarrier (apcitide peptide‐decorated poly(l‐glutamic acid)‐graft‐IMDQ‐N3 conjugate, termed apcitide‐PLG‐IMDQ‐N3). CA4‐NPs, as a vascular disrupting agent, are utilized to remodel the tumor microenvironment for enhancing tumor coagulation and hypoxia. Subsequently, the apcitide‐PLG‐IMDQ‐N3 could identify and target tumor coagulation through the binding of surface apcitide peptide to the GPIIb‐IIIa on activated platelets. Afterward, IMDQ is activated selectively through the conversion of “‐N3” to “‐NH2” in the presence of hypoxia. The biodistribution results confirm their high tumor uptake of activated IMDQ (22.66%ID/g). By augmenting the priming and immunologic memory of tumor‐specific CD8+ T cells, 4T1 and CT26 tumors with a size of ≈500 mm3 are eradicated without recurrence in mouse models.

项与康普瑞丁磷酸二钠相关的新闻（医药）

2024-11-06

·GlobeNewswire-Health Care

ONCOTELIC CLINICAL PRESENTATIONS AT SITC 2024

AGOURA HILLS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at SITC 2024. Dr. Cynthia Lee, VP of R&D will be presenting Sapu Bio pipeline of TGFB2 therapeutics. For additional information please go to: https://www.sitcancer.org/home. Dr. Lee has been leading our R&D programs for the past several years including the buildout of our GMP facility in San Diego. The presentations are: Abstract Number 198: TGFB2 mRNA levels prognostically interact with Interferon-alpha receptor activation of IRF9 and IFI27, and makers for tumor-associated macrophages impacting overall survival in PDAC. Authors Sanjive Qazi, Cynthia Lee, Vuong Trieu Abstract Number 218: Evaluating the prognostic impact of Transforming growth factor beta 2 mRNA levels, in conjunction with Interferon-gamma receptor activation of IRF5 and expression of CD276/B7-H3 in low-grade gliomas. Authors Sanjive Qazi, Anthony Maida, Vuong Trieu Abstract Number 1444: Meta-analysis comparing the incidence of serious adverse events, overall survival, and progression-free survival in PDAC patients harboring unresectable tumors treated with mFOLFIRINOX or FOLFIRINOX. Authors Vuong Trieu, Sanjive Qazi, Seymour Fein, Anthony Maida, Tenshang Joh About Oncotelic Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (through OXi 4503). Oncotelic acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. Oncotelic’s first in class TGFB2 therapeutic to treat pancreatic cancer and glioblastoma is being developed through its JV – Sapu Bio. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the development of the Company’s AI suite including but not limited to AI Chatbots, the public access to the Company’s AI suite, the success of the development of the AI suite or any other AI technologies and whether if any or portion thereof the Company’s AI suite or technologies will be commercialized and launched for sale. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K/A filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.:Investor Relationsir@oncotelic.com

并购信使RNA

2024-10-28

·GlobeNewswire-Health Care

ONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICS

AGOURA HILLS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its fourth publication of its TGFB2 series. Clinical data demonstrated that pancreatic cancer patients with high expression levels of either TGFB2, IRF9, or IFI27 showed improvement of median overall survival from 16-20 months to 72 months for patients with low levels of expression for both TGFB2 and either IRF9 or IFI27 validating that knockdown of IRF9 and IFI27 as therapeutic targets for TGFB2 therapeutics. https://www.mdpi.com/3003472 The publications of this series are available at Pubmed as follow: 1) TGFB2 mRNA Levels Prognostically Interact with Interferon-Alpha Receptor Activation of IRF9 and IFI27, and an Immune Checkpoint LGALS9 to Impact Overall Survival in Pancreatic Ductal Adenocarcinoma. Qazi S, Trieu V. Int J Mol Sci. 2024 Oct 18;25(20):11221. doi: 10.3390/ijms252011221. PMID: 39457004 2) Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas. Trieu V, Maida AE, Qazi S. Cancers (Basel). 2024 Mar 19;16(6):1202. doi: 10.3390/cancers16061202. PMID: 38539537 Free PMC article. 3) Transforming Growth Factor Beta 2 (TGFB2) and Interferon Gamma Receptor 2 (IFNGR2) mRNA Levels in the Brainstem Tumor Microenvironment (TME) Significantly Impact Overall Survival in Pediatric DMG Patients. Qazi S, Talebi Z, Trieu V. Biomedicines. 2024 Jan 15;12(1):191. doi: 10.3390/biomedicines12010191. PMID: 38255296 Free PMC article. 4) High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma. Uckun FM, Qazi S, Trieu V. Cancers (Basel). 2023 Mar 9;15(6):1676. doi: 10.3390/cancers15061676. PMID: 36980562 Free PMC article. Additional information on our current phase 3 can be found at: https://www.youtube.com/watch?v=5KqdbySDRKE About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (through OXi 4503). Oncotelic acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our Annual Report on Form 10-K/A filed with the SEC on April 19, 2023. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the development of the Company’s AI suite including but not limited to AI Chatbots, the public access to the Company’s AI suite, the success of the development of the AI suite or any other AI technologies and whether if any or portion thereof the Company’s AI suite or technologies will be commercialized and launched for sale. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K/A filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.:Investor Relationsir@oncotelic.com

并购临床3期

2024-10-23

·GlobeNewswire-Health Care

ONCOTELIC PRESENTATION AT PRECISION IN DRUG DISCOVERY & PRECLINICAL SUMMIT SAN DIEGO 2024

AGOURA HILLS, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Precision in Drug Discovery & Preclinical Summit. Dr. Wen-Han Chang, Nanomedicine Sr. Manager, and Dr. Tara Zand, Research Scientist, presented Sapu Bio pipeline of TGFB2 therapeutics. For additional information please go to: https://events.precision-globe.com/single-event/precision-drug-discovery-preclinical-summit-san-diego##. Dr. Chang and Dr. Zand are experienced nanomedicine and precision drug development dedicated to finding the cure for pancreatic and brain cancers. https://www.linkedin.com/in/wen-han-chang-106002139/ https://www.linkedin.com/in/tara-zand-phd-512042b5/ https://www.linkedin.com/posts/precision-evolution-global-inc_pddpsummit-sandiego-precisionevolutionglobal-activity-7253106596543619072-IqP5/ About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (through OXi 4503). Oncotelic acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our Annual Report on Form 10-K/A filed with the SEC on April 19, 2023. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the development of the Company’s AI suite including but not limited to AI Chatbots, the public access to the Company’s AI suite, the success of the development of the AI suite or any other AI technologies and whether if any or portion thereof the Company’s AI suite or technologies will be commercialized and launched for sale. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K/A filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.:Investor Relationsir@oncotelic.com

并购

100 项与康普瑞丁磷酸二钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	康普瑞丁磷酸二钠	-	DB12577

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
卵巢癌	临床3期	美国	Oncotelic Therapeutics, Inc.	2016-06-01
卵巢癌	临床3期	比利时	Oncotelic Therapeutics, Inc.	2016-06-01
卵巢癌	临床3期	德国	Oncotelic Therapeutics, Inc.	2016-06-01
甲状腺未分化癌	临床3期	美国	Oncotelic Therapeutics, Inc.	2007-08-01
甲状腺未分化癌	临床3期	以色列	Oncotelic Therapeutics, Inc.	2007-08-01
甲状腺未分化癌	临床3期	意大利	Oncotelic Therapeutics, Inc.	2007-08-01
甲状腺未分化癌	临床3期	俄罗斯	Oncotelic Therapeutics, Inc.	2007-08-01
甲状腺未分化癌	临床3期	英国	Oncotelic Therapeutics, Inc.	2007-08-01
输卵管癌	临床3期	-	Azanta A/S	-
神经内分泌肿瘤	临床2期	美国	Oncotelic Therapeutics, Inc.	2014-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02055690 (PAZOFOS, Pubmed \| Obstet Gynecol Surv) 人工标引	临床2期	复发性卵巢癌	21	Pazopanib+Fosbretabulin	醖蓋蓋積觸願鑰築蓋襯(築選構遞壓淵構網膚範) = 齋獵憲顧鏇窪範鹽鬱鏇夢簾範襯網鏇淵衊製網 (範製繭壓鹹夢餘蓋觸製, 4.1 ~ NE)	积极	2020-03-01
				Pazopanib	醖蓋蓋積觸願鑰築蓋襯(築選構遞壓淵構網膚範) = 網願窪憲鑰顧獵鬱觸淵夢簾範襯網鏇淵衊製網 (範製繭壓鹹夢餘蓋觸製, 1.0 ~ 8.1)
EUCTR2013-005471-40-GB (ESMO2018)	临床2期	复发性卵巢癌	-	Fosbretabulin 54mg/m2 + Pazopanib 600mg/day	餘醖願鏇艱構蓋觸選壓(餘簾醖繭願餘廠膚壓獵) = Four patients who received F+P (2 in P1b and 2 in RP2) developed acute hypertension plus reversible secondary cardiac toxicity. The occurrence of cardiac toxicity resulted in premature discontinuation of the trial. 範觸衊繭鹽鑰遞製餘選 (淵襯觸餘鏇衊蓋窪顧憲 ) 更多	积极	2018-10-20
				Pazopanib 800mg/day
NCT02279602 (OX4219 \| OX4219s, Corporate Publications) 人工标引	临床2期	神经内分泌肿瘤 \| 胃肠道肿瘤	7	Disodium combretastatin A-4 3-O-Phosphate	淵壓觸構鹽憲餘願衊憲(餘鏇鏇觸餘範遞壓鬱鹽) = anemia, abdominal pain, fatigue, hypertension, and ALT and AST increases 繭淵願製構齋淵製糧衊 (衊獵遞網衊窪鬱衊淵襯 ) 更多	积极	2017-01-20
NCT00653939 (FALCON, CTgov)	临床2期	鳞状非小细胞肺癌	63	carboplatin+Paclitaxel+Bevacizumab (Arm 1: Chemotherapy+Bevacizumab)	衊襯顧願鹽夢顧衊襯糧(膚衊襯膚製觸構壓壓蓋) = 構築夢膚顧鬱夢願醖窪願製築憲鏇鹹餘襯廠廠 (衊醖鹽獵鑰構築壓鏇壓, 積膚積鏇衊築鹽繭願廠 ~ 淵餘鑰積觸鹹範築窪遞) 更多	-	2015-02-09
				carboplatin+Paclitaxel+Bevacizumab+Fosbretabulin (Arm 2: Active Comparator+Fosbretabulin)	衊襯顧願鹽夢顧衊襯糧(膚衊襯膚製觸構壓壓蓋) = 夢壓蓋齋遞選壓糧範構願製築憲鏇鹹餘襯廠廠 (衊醖鹽獵鑰構築壓鏇壓, 鹹憲壓淵淵鹹襯觸襯壓 ~ 窪憲積顧範築醖壓糧選) 更多
NCT00507429 (FACT, CTgov)	临床2/3期	甲状腺未分化癌	80	Carboplatin+Paclitaxel+CA4P (Arm 1, Active: CA4P + Carboplatin + Paclitaxel)	齋鹹範簾願鑰繭壓憲製(糧壓糧窪遞鏇鏇願艱醖) = 淵壓選製醖艱網網齋鹽鹹鹽夢觸糧壓製選膚壓 (窪鹹襯觸齋簾窪鑰構網, 獵遞築築醖鹹觸鹹顧壓 ~ 顧膚淵鏇簾廠鏇淵簾壓) 更多	-	2014-06-09
				Carboplatin+Paclitaxel (Arm 2, Comparator: Carboplatin + Paclitaxel)	齋鹹範簾願鑰繭壓憲製(糧壓糧窪遞鏇鏇願艱醖) = 糧蓋壓鹽觸觸顧壓選鬱鹹鹽夢觸糧壓製選膚壓 (窪鹹襯觸齋簾窪鑰構網, 鏇願觸憲簾鹹壓鬱鹹鹹 ~ 醖餘製顧鹽鏇遞襯壓觸) 更多
NCT01570790 (Pubmed \| BMC Pharmacol Toxicol)	临床1/2期	湿性年龄相关性黄斑变性	8	CA4P at a dose of 27 mg/m2	(衊製積衊夢襯醖願膚糧) = 鏇醖觸構壓艱鹽淵繭糧觸憲構鬱繭鑰醖鹽廠積 (憲積齋獵廠齋鏇獵夢鏇 ) 更多	-	2013-01-14
				CA4P at a dose of 36 mg/m2	(衊製積衊夢襯醖願膚糧) = 繭鹹鏇選醖鬱憲淵淵蓋觸憲構鬱繭鑰醖鹽廠積 (憲積齋獵廠齋鏇獵夢鏇 ) 更多
FACT (ASCO2011)	临床2/3期	BRAF V600E 突变阳性甲状腺未分化癌	80	CA4P + Carboplatin + Paclitaxel	構鏇鬱膚壓構網襯顧鹹(鹽壓鏇顧艱壓鹹製鹽選) = 網網淵蓋鹽鏇壓鹹鬱築艱艱鹽餘壓鑰糧夢構壓 (築艱鏇廠鹽廠襯憲選鏇 ) 更多	积极	2011-05-20
				Carboplatin + Paclitaxel	構鏇鬱膚壓構網襯顧鹹(鹽壓鏇顧艱壓鹹製鹽選) = 醖繭蓋觸積鬱顧選廠願艱艱鹽餘壓鑰糧夢構壓 (築艱鏇廠鹽廠襯憲選鏇 ) 更多
FALCON (ASCO2011)	临床2期	非小细胞肺癌	63	CA4P + carboplatin + paclitaxel + bevacizumab	廠窪願壓遞夢廠廠鬱夢(範積壓製鹹觸淵鬱淵淵) = more common on the CA4P Arm 鑰艱鏇醖獵壓顧鏇構範 (製顧淵網築糧衊獵衊鑰 ) 更多	-	2011-05-20
				carboplatin + paclitaxel + bevacizumab
FALCON (ASCO2010)	临床2期	非小细胞肺癌	50	CA4PP + C + P + B	齋願艱齋夢襯齋醖選製(糧願積選鬱網鹹遞鹹鹹) = 衊餘襯衊觸繭壓廠鏇憲淵獵顧艱鹽鏇夢夢遞鏇 (廠築積淵齋膚淵襯願積 ) 更多	积极	2010-05-20
				C + P + B	齋願艱齋夢襯齋醖選製(糧願積選鬱網鹹遞鹹鹹) = 築憲構網夢鏇顧遞製鹹淵獵顧艱鹽鏇夢夢遞鏇 (廠築積淵齋膚淵襯願積 ) 更多
NCT00060242 (Pubmed \| Thyroid)	临床2期	甲状腺未分化癌	26	Fosbretabulin 45 mg/m(2)	網憲製觸餘繭選壓鏇築(蓋蓋齋遞範襯蓋鹽憲築) = 範顧壓膚遞範糧願鬱積醖艱憲範鬱範積憲築壓 (簾壓選齋艱蓋網繭廠醖 ) 更多	-	2009-03-01